W
WAVEMAN · COMPANY
LUNG · Pulmonx Corp
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

LUNG

Pulmonx Corp
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001127537
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$321.1K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
55
13F, latest reported quarter
REVENUE GROWTH
+8.0%
XBRL, annual
NET MARGIN
-59.7%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$321.1K over 180 days
-$177.0K over 90 days
below 51% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
55 funds added or opened last quarter
below 60% of Medical Devices
REVENUE
+8.0% year over year
more than 50% of Medical Devices
MARGIN
-59.7% net margin
below 75% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
2.5% of shares outstanding short · 1.4 days to cover · settled 2026-07-31
below 57% of Medical Devices
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$321.1K across 4 people in 180 days.
55 funds added or opened positions in the latest 13F quarter, of 108 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +27.7%
+27.7%12M
-32%-5%+23%+50%2025-092025-102025-122026-032026-052026-072026-09 2026-09-01 · French Glendon E. III sold $85.4K2026-03-02 · French Glendon E. III sold $83.5K2026-06-01 · French Glendon E. III sold $59.2K2025-12-08 · Florin Daniel P sold $46.4K2026-06-02 · French Glendon E. III sold $21.2K2026-09-01 · Radhakrishnan Srikanth sold $13.3K2026-09-01 · Lehman David Aaron sold $10.9K2025-12-01 · French Glendon E. III sold $9.9K2026-03-02 · French Glendon E. III sold $9.6K2026-09-01 · French Glendon E. III sold $9.3K2026-06-01 · Radhakrishnan Srikanth sold $9.2K2026-09-01 · Lehman David Aaron sold $8.6K2025-09-02 · Williamson Steven S. sold $8.2K2026-09-01 · Radhakrishnan Srikanth sold $8.2K2026-09-01 · Lehman David Aaron sold $7.9K2026-06-01 · Lehman David Aaron sold $7.6K2025-09-02 · Williamson Steven S. sold $7.2K2025-09-02 · Joshi Mehul sold $6.8K2026-06-01 · French Glendon E. III sold $6.4K2026-03-02 · Lehman David Aaron sold $6.3K2026-03-02 · Radhakrishnan Srikanth sold $6.0K2026-09-01 · Radhakrishnan Srikanth sold $6.0K2026-06-01 · Lehman David Aaron sold $6.0K2025-09-02 · Joshi Mehul sold $5.9K2025-12-01 · Lehman David Aaron sold $5.8K2026-03-02 · Lehman David Aaron sold $5.8K2026-06-01 · Radhakrishnan Srikanth sold $5.7K2025-09-02 · Lehman David Aaron sold $5.7K2026-06-01 · Lehman David Aaron sold $5.5K2026-09-01 · Rose Geoffrey Beran sold $5.4K2025-12-01 · Lehman David Aaron sold $5.3K2025-09-02 · Lehman David Aaron sold $5.2K2026-09-01 · Lehman David Aaron sold $5.0K2026-09-01 · Rose Geoffrey Beran sold $5.0K2026-09-01 · Radhakrishnan Srikanth sold $4.8K2026-03-02 · Radhakrishnan Srikanth sold $4.4K2026-03-02 · Rose Geoffrey Beran sold $4.2K2026-06-01 · Radhakrishnan Srikanth sold $4.1K2025-12-01 · French Glendon E. III sold $4.0K2026-09-01 · Rose Geoffrey Beran sold $3.9K2025-09-02 · Rose Geoffrey Beran sold $3.9K2026-03-02 · French Glendon E. III sold $3.9K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $321.1K sold by insiders over 180 days, 55 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Pulmonx Corp insiders sold a net $321.1K of stock across 287 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Lehman David Aaron
General Counsel
SELL
2026-09-01
3,807.0
$8.6K
Lehman David Aaron
General Counsel
SELL
2026-09-01
2,224.0
$5.0K
Lehman David Aaron
General Counsel
SELL
2026-09-01
3,476.0
$7.9K
Lehman David Aaron
General Counsel
SELL
2026-09-01
4,827.0
$10.9K
Rose Geoffrey Beran
Chief Commercial Officer
SELL
2026-09-01
2,213.0
$5.0K
287 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 282 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
PRIMECAP MANAGEMENT CO/CA/
4,612,331.0 sh
$6.0M
MORGAN STANLEY
2,922,921.0 sh
$3.8M
Soleus Capital Management, L.P.
2,788,323.0 sh
$3.6M
Stonepine Capital Management, LLC
1,630,872.0 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
1,630,219.0 sh
$2.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
PRIMECAP Odyssey Aggressive Growth Fund
$4.6M POSITION · AS OF 2026-04-30
0.1%
Ultra-Small Company Market Fund
$78.7K POSITION · AS OF 2026-03-31
0.1%
JPMorgan U.S. Small Company Fund
$187.7K POSITION · AS OF 2026-03-31
0.0%
LVIP JPMorgan Small Cap Core Fund
$41.3K POSITION · AS OF 2026-03-31
0.0%
VY(R) JPMORGAN SMALL CAP CORE EQUITY PORTFOLIO
$27.1K POSITION · AS OF 2026-03-31
0.0%
iShares Micro-Cap ETF
$117.9K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 8 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
8
Not applicable
3 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$90.5M$83.8M$68.7M$53.7M
GROSS PROFIT$67.1M$62.0M$50.8M$39.9M
OPERATING INCOME$-53.7M$-57.7M$-61.9M$-58.6M
NET INCOME$-54.0M$-56.4M$-60.8M$-58.9M
EPS (DILUTED)-1.33-1.44-1.60-1.59
OPERATING CASH FLOW$-32.4M$-31.5M$-37.6M$-45.1M
CASH$69.8M$70.9M$83.5M$101.7M
LONG-TERM DEBT$37.0M$34.0M$35.1M$17.2M
BUYBACKS——$0$27.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →